Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
BCL2 expression
Cancer:
Diffuse Large B Cell Lymphoma
Drug:
Venclexta (venetoclax)
(
Bcl2 inhibitor
) +
S63845
(
MCL1 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
EHA 2020
Title:
TARGETING ANTI-APOPTOTIC MCL1 PROTEIN WITH S63845 IS HIGHLY EFFECTIVE IN AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS WITH NON-EXPRESSION OF BCL2
Published date:
06/12/2020
Excerpt:
...co-targeting of MCL1 and BCL2 (with S63845 and venetoclax) induced additive to synergistic anti-lymphoma effect in all tested PDX models.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login